Article Text

Download PDFPDF

Long-Term Pain and Functional Disability After Total Knee Arthroplasty With and Without Single-Injection or Continuous Sciatic Nerve Block in Addition to Continuous Femoral Nerve Block: A Prospective, 1-Year Follow-Up of a Randomized Controlled Trial
  1. Jessica T. Wegener, MD*,
  2. Bas van Ooij, MD,
  3. C. Niek van Dijk, MD, PhD,
  4. Sabina A. Karayeva*,
  5. Markus W. Hollmann, MD, PhD*,
  6. Benedikt Preckel, MD, MA* and
  7. Markus F. Stevens, MD, PhD*
  1. *Department of Anesthesiology, Academic Medical Center, University of Amsterdam, and †Department of Orthopedic Surgery, Academic Medical Center and the Orthopedic Research Center, Amsterdam, the Netherlands.
  1. Address correspondence to: Benedikt Preckel, MD, MA, Department of Anesthesiology Academic Medical Center, Meibergdreef 9 1100DD, Amsterdam, the Netherlands (e-mail: b.preckel{at}amc.uva.nl).

Abstract

Background and Objectives This is a follow-up to determine long-term outcomes after total knee arthroplasty (TKA) in patients enrolled in a previous randomized trial that found reduced postoperative pain after addition of sciatic nerve block to continuous femoral nerve block for TKA.

Methods Physical function after TKA was evaluated at 3 and 12 months in patients (n = 89) receiving continuous femoral nerve block alone (group F), combined with a single-injection (group Fs) or continuous sciatic nerve block (group FCS) after TKA, until the second postoperative day. Physical function, stiffness, and pain were measured by using Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), Oxford Knee Score 12-item knee questionnaires, and visual analog scale at rest and during mobilization before TKA and 3 and 12 months afterward. Post hoc, a median split on poor functioning (WOMAC) was analyzed.

Results Western Ontario and McMaster Universities Osteoarthritis Index, Oxford Knee Score 12-item knee, and visual analog scale scores improved significantly in all patients, without any differences among groups. Median (range) WOMAC at 3 months were in group F, 83 (20–97); group Fs, 72 (25–99); and group, FCS 76 (28–100) and at 12 months 87 (35–98), 77 (43–100), and 89 (35–100), respectively.

Conclusions No differences were detected in the secondary outcomes we examined. Thus, improved postoperative outcome did not translate into improved functional outcome or long-term pain.

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Footnotes

  • Support was provided solely from institutional sources.

    The authors declare no conflict of interest.

    Joseph M. Neal, MD, served as editor-in-chief for this article.